PET imaging biomarkers in head and neck cancer

Malene Hildebrandt, Oke Gerke, Christina Baun, Kirsten Falch Braas, J Ansholm, Ziba Farahani, L Larsen, Sandra Duvnjak, Kent S, Anne Marie Bak Jylling, Marianne Ewertz, Abass Alavi, Poul Flemming Høilund-Carlsen

Research output: Contribution to journalJournal articleResearchpeer-review


In locally advanced head and neck squamous cell carcinoma (HNSCC), the role of imaging becomes more and more critical in the management process. In this framework, molecular imaging techniques such as PET allow noninvasive assessment of a range of tumour biomarkers such as metabolism, hypoxia and proliferation, which can serve different purposes. First, in a pretreatment setting they can influence therapy selection strategies and target delineation for radiation therapy. Second, their predictive and/or prognostic value could help enhance the therapeutic ratio in the management of HNSCC. Third, treatment modification can be performed through the generation of a molecular-based heterogeneous dose distribution with dose escalation to the most resistant parts of the tumour, a concept known as dose painting. Fourth, they are increasingly becoming a tool for monitoring response to therapy. In this review, PET imaging biomarkers used in the routine management of HNSCC or under investigation are discussed.

Original languageEnglish
Article numberP573
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Pages (from-to)613-622
Publication statusPublished - 2015
Event28th Annual Congress of the European Association of Nuclear Medicine - Hamburg, Germany
Duration: 10. Oct 201514. Oct 2015
Conference number: 28


Conference28th Annual Congress of the European Association of Nuclear Medicine


  • Head and neck cancer
  • Imaging biomarker
  • PET/CT


Dive into the research topics of 'PET imaging biomarkers in head and neck cancer'. Together they form a unique fingerprint.

Cite this